Related Experiment Video
Updated: May 4, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics
Dimitri P Mikhailidis1, Vasilios G Athyros2
1Department of Clinical Biochemistry (Vascular Prevention Clinic), Royal Free Hospital Campus, University College School of Medicine, Pond Street, London NW3 2QG, UK.
Abstract:
The new ACC/AHA guidelines on treatment of blood cholesterol focus on intensity of statin therapy rather than target levels of lipids. Early studies show substantial reductions in LDL-cholesterol level with antibodies against PCSK9. MicroRNA silencing and gene-repair techniques to treat dyslipidaemia are promising strategies under development.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Pharmacogenomics: Identification of New Drug Targets
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis I: Introduction

